Goldman Sachs’s AMAG Pharmaceuticals AMAG Stock Holding History

Goldman Sachs’s Portfolio AMAG Stock Details AMAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-67,200	Closed	-$776K	–	5495
2019 Q3	$776K	Hold	67,200	–	–	﹤0.01%	4186
2019 Q2	$671K	Buy	+67,200	New	+$725K	﹤0.01%	4247
2016 Q3	–	Sell	-15,700	Closed	-$376K	–	7267
2016 Q2	$376K	Buy	+15,700	New	+$360K	﹤0.01%	5130
2014 Q4	–	Sell	-40,000	Closed	-$1.28M	–	7405
2014 Q3	$1.28M	Sell	40,000 -13,200	-25%	-$281K	﹤0.01%	4367
2014 Q2	$1.1M	Hold	53,200	–	–	﹤0.01%	4604
2014 Q1	$1.03M	Buy	53,200 +26,500	+99%	+$563K	﹤0.01%	4652
2013 Q4	$648K	Buy	+26,700	New	+$628K	﹤0.01%	5101

Goldman Sachs's AMAG Position: Q4 2020 in Review

Goldman Sachs sold out of AMAG Pharmaceuticals (AMAG) in Q4 2020, closing a stake of 2,021,177 shares — an estimated $19M sold.

Goldman Sachs first reported a position in AMAG in Q2 2013 and held it in 30 quarters. The position peaked at $25.4M in Q4 2019. 1 fund tracked by Wall St. Rank holds AMAG as of Q4 2020.

Goldman Sachs reported no remaining AMAG Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Goldman Sachs sold 2,021,177 AMAG Pharmaceuticals shares in Q4 2020, an estimated $19M.
Goldman Sachs first reported a position in AMAG Pharmaceuticals in Q2 2013 and held it in 30 quarters.
Goldman Sachs's AMAG Pharmaceuticals position peaked at $25.4M in Q4 2019.
1 fund tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2020.

Based on Goldman Sachs's 13F filing for Q4 2020, filed 12 Feb 2021.